Key Considerations When Selling Your Business to a Private Equity Buyer

Medtech companies are confronting growing tension between the need to maintain trade secret protection and the obligation to disclose extensive information for FDA approval. Member William Meunier and Of Counsels Carolina Säve and Benjamin Zegarelli detail where sensitive material is most at risk across FDA submissions, how the Defend Trade Secrets Act and the Freedom of Information Act shape that exposure, and the practical strategies companies can use to navigate the submission process without compromising proprietary information.

Recent directives could shift how the Federal Trade Commission approaches AI oversight, including its role in consumer protection and antitrust enforcement. In AI: The Washington Report, Antitrust Co-chair Bruce Sokler and ML Strategies’ Executive Vice President & Director of Operations Alexander Hecht and Senior Vice President Christian Tamotsu Fjeld, analyze what these potential rollbacks may mean for innovators, consumers, and competition in the AI sector.

Sustainable Energy & Infrastructure Connections delivers insights for companies and investors on the future of energy and infrastructure. The August edition, authored by Sustainable Energy & Infrastructure Chair Thomas Burton, Sustainable Energy & Infrastructure Co-chair Sahir Surmeli, and Of Counsel Lyndon Plothow, covers the tax implications of the new One Big Beautiful Bill Act, key M&A activity, litigation trends, Washington policy updates, and a spotlight on The Metals Company’s critical resource exploration.

What does it take to serve on a private equity board — and is it the right move? San Francisco Managing Member Steve Osborn brought together leading voices at a National Association of Corporate Directors panel to examine the risks and rewards, how PE boards are structured, and what directors should expect when it comes to compensation, independence, and navigating high-stakes challenges.

Biopharma dealmaking is shifting, with companies turning to new strategies to balance risk and growth. International Life Sciences Chair Cheryl Reicin joined the Scrip M&A Podcast to discuss how major pharmaceutical companies are using license and option agreements to manage risk, build pipelines, and prepare for future acquisitions amid market uncertainty.

Workplace investigations can shape how employees view fairness, transparency, and leadership. In this episode of Mintz on Air, Members Jen Rubin and Natashia Tidwell share practical guidance on defining scope, ensuring objectivity, knowing when to bring in outside help, and why clear communication is critical to a successful investigation.